CSG tops earnings and revenue estimates, confirms outlook; shares slide

Revenue surged 72% to €6.74bn (organic +30%), ~5% above consensus and company guidance of €6.4bn; adjusted EBIT rose to €1.63bn (+31% organic) with a 24.1% margin at the low end of guidance. Net profit was €694.1m (+~35%), pretax €1.18bn, and pre-tax free cash flow €61m; order backlog stood at €15bn. CSG reaffirmed 2026 revenue guidance of €7.4–7.6bn and cites benefits from elevated defense spending and the Kinetic Group integration, but shares fell ~5.6% despite the beat.

Analysis

CSG’s post-IPO sell-off despite an operational beat is signaling market concern about cash conversion and backlog composition rather than top-line durability. The Kinetic integration shifts the company from regional to transatlantic scale, which should pressure midsize ammo incumbents across Europe and North America to consolidate or specialize; expect pricing power to migrate toward large, integrated producers over 6–24 months.

Second-order supply effects matter: raw-material chains (brass/copper, propellant chemicals, precision steel) will see uneven demand shocks as governments refill stockpiles, creating input-cost volatility and potential bottlenecks that can compress margins episodically. Watch working-capital flows — the reported FCF seasonality is likely to normalize over two quarters, but any repeatable downside would force a larger multiple haircut.

Key catalysts/timelines: near term (days–weeks) look for sentiment-driven volatility around investor calls and analyst re-estimates; medium term (3–12 months) focus on backlog conversion rates, margin trajectory across product mix, and realized synergies from Kinetic; long term (12–36 months) the structural reallocation of defense spend toward ammunition should support higher steady-state utilization and potentially re-rate multiples. The market may be overly focused on one quarter’s FCF noise and underweight the multi-year revenue visibility embedded in the backlog; conversely, integration execution and input-cost risk are real paths to derate the name further.

Key Decisions for Investors

• Long CSG.AS equity (size 1–2% NAV). Timeframe 6–12 months. Thesis: backlog visibility + Kinetic synergies -> multiple expansion; target +30% upside. Risk management: hard stop at -15% from entry or trim if FCF misses two consecutive quarters.
• Relative-value pair: Long CSG.AS / Short RHM.DE (net market-neutral exposure, equal notional). Timeframe 9–12 months. Thesis: pure-play ammunition and US integration re-rate faster than diversified prime; expected asymmetric return ~2:1 if spread widens. Stop-loss: tighten if spread moves against position by >10% or if RHM announces major ammunition-focused M&A.
• Options hedge: Buy 12-month CSG.AS call spread funded by selling nearer-term calls (calendar spread sized to <1% NAV). Timeframe 6–12 months. Thesis: caps downside premium while keeping upside convexity if backlog converts and FCF normalizes; target gross upside 3–4x premium, loss limited to premium paid.